2018
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts
Yoon JT, Longtine MS, Marquez-Nostra BV, Wahl RL. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts. Journal Of Nuclear Medicine 2018, 59: 1219-1224. PMID: 29348316, PMCID: PMC6071500, DOI: 10.2967/jnumed.117.203299.Peer-Reviewed Original ResearchConceptsTumor uptakeCD20 antibodyLymphoma xenograftsMonoclonal antibodiesDrug AdministrationBurkitt's lymphoma xenograftsHigher splenic uptakeAnti-CD20 antibodyCD20 monoclonal antibodyPET/CT imagingHuman lymphoma xenograftsSmall-animal PET/CT imagesPreclinical mouse modelsB-cell lymphomaPET/CTPET/CT imagesHigh tumor uptakeNext-Generation AntiClear tumor uptakePalpable tumorsSplenic uptakeImmunodeficient miceEffective treatmentMouse modelObinutuzumab
2017
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent
Marquez-Nostra BV, Lee S, Laforest R, Vitale L, Nie X, Hyrc K, Keler T, Hawthorne T, Hoog J, Li S, Dehdashti F, X. C, Lapi SE. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. Oncotarget 2017, 5: 104303-104314. PMID: 29262642, PMCID: PMC5732808, DOI: 10.18632/oncotarget.22228.Peer-Reviewed Original ResearchTriple-negative breast cancerMDA-MB-468 xenograftsNegative breast cancerCDX-011Breast cancerMean SUVTumor uptakePatient-derived xenograft modelsDiagnostic imaging agentsGPNMB expressionMDA-MB-231 tumorsSelection of patientsTNBC cell linesImaging agentGlembatumumab vedotinPDX micePharmacologic propertiesPreclinical studiesXenograft modelTargeted treatmentMelanoma BDays p.Preclinical PET imagingUptake correlatesEffective dose